SCHEDULE: Vanguard Group Amends Heron Therapeutics Stake to Zero
Beneficial Ownership Amendment
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Heron Therapeutics Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Heron Therapeutics Inc. common stock.
- The filing reports 0% beneficial ownership of Heron Therapeutics Inc. by The Vanguard Group.
- This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event for Heron Therapeutics, as the change reflects an internal administrative realignment by The Vanguard Group rather than a divestment based on Heron's performance or prospects. The impact is primarily on reporting structure.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that such internal realignments by large asset managers like The Vanguard Group are not uncommon and typically reflect internal operational or regulatory compliance adjustments rather than a change in investment thesis regarding the underlying company, Heron Therapeutics. However, the disaggregation means the parent entity no longer reports a direct stake, which could be misinterpreted if the context of the realignment is overlooked.
Stakeholder Impact
- Shareholders of Heron Therapeutics Inc. should understand that The Vanguard Group's reported 0% beneficial ownership is due to an internal reporting realignment, not a complete divestment of all underlying Vanguard-managed funds' holdings. Individual Vanguard funds may still hold shares, but the parent entity no longer aggregates and reports them under this Schedule 13G.
Key Dates
| Date | Description |
|---|---|
| 01/12/2026 | The Vanguard Group, Inc. internal realignment date. |
| 03/13/2026 | Date of event requiring the filing of this statement. |
| 03/27/2026 | Signature date of the filing. |
Keywords
Heron Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, HTBX
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.